Outpatient Surgery Magazine

The Case for Concurrent Cases - November 2018 - Subscribe to Outpatient Surgery Magazine

Outpatient Surgery Magazine, providing current information on Surgical Services, Surgical Facility Administration, Outpatient Surgery News and Trends, OR Excellence and more.

Issue link: http://magazine.outpatientsurgery.net/i/1051811

Contents of this Issue

Navigation

Page 73 of 136

7 4 • O U T PA T I E N T S U R G E R Y M A G A Z I N E • N O V E M B E R 2 0 1 8 What's New in Cataract Medications A look at 6 new drugs your surgeons might want to try. Dan O'Connor | Editor-in-Chief I n cataract surgery, there's a drug for that. For dropless and for sutureless. For pre-op sedation and for pupil dilation. And, of course, for pain. Here's a review of 6 relatively new medications your eye doctors might soon want to use. In alphabetical order: Dextenza, Dexycu, Inveltys, MKO Melt, Omidria and ReSure Sealant. Dextenza Dextenza (dexametha- sone insert) 0.4mg is a corticosteroid intra- canalicular insert that the surgeon places through the punctum into the canaliculus to treat ocular pain. It's designed to deliver a tapered dose of dex- amethasone to the ocular surface for up to 30 days without preservatives, says Ocular Therapeutix. Following treatment, Dextenza is intended to resorb and exit the nasolacrimal system without the need for removal. Dextenza has completed Phase 3 evaluation for the treatment of ocular pain and inflammation following ophthalmic surgery, but is cur- rently limited to investigational use only. Dexycu Dexycu (dexamethasone intraocular suspension) 9% is an extended- • PUNCTUM PAIN INSERT Dextenza (dexamethasone insert) 0.4mg is a corticosteroid intracanalicular insert placed through the punctum for the treatment of ocular pain and inflammation following ophthalmic surgery. Ocular Therapeutix

Articles in this issue

Archives of this issue

view archives of Outpatient Surgery Magazine - The Case for Concurrent Cases - November 2018 - Subscribe to Outpatient Surgery Magazine